# Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

> **NCT02620800** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 12 (actual)

## Conditions studied

- Metastatic Pancreas Adenocarcinoma

## Interventions

- **DRUG:** 5FU
- **DRUG:** nab-paclitaxel
- **DRUG:** bevacizumab
- **DRUG:** calcium leucovorin
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT02620800
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-18
- **Primary completion:** 2018-10-29
- **Final completion:** 2018-10-29
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620800, "Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02620800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*